Drugs / PEG-liposomal prednisolone sodium phosphate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01039103 | Dec 2009 → Nov 2011 | relapsing-remitting multiple sclerosis | Lakefront Biotherapeutics NV | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEG-liposomal prednisolone sodium phosphate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01039103 ↗ |
| Route | Intravenous | “300 mg intravenous (IV), single dose” NCT01039103 ↗ |